Something is brewing, Is it a partnership? Could it be.
TAKEDA
First why Takeda
They already have Alofisel however this product is made to order and has a life of just a few days.
They also sell Entyvio. This one Is huge for them, and by the look of our IBD trials MSCs could have a significant impact on sales.
And just how competitive would Remestemcell-L be ?
Well the price tag is going to be reasonably competitive I believe. First year on Entyvio costs $26320 and will give you a good list of side effects for no additional fee.
https://www.ncbi.nlm.nih.gov/books/NBK424364/table/T68/
Add the many other indications that Remestemcell-L could be developed for and one can see the huge market potential it has.
Good luck all
MSB 2022 - The road to commercialisation, page-520
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
-0.010(0.69%) |
Mkt cap ! $1.644B | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.50 | $1.43 | $4.048M | 2.778M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 26808 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 16001 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |